By Editorial Team
CityReported
City aims to lay foundation for RNAi renaissance with nearly $100M series B.
The round
City, a biotechnology firm, has successfully closed a Series B funding round, securing approximately $100 million. The company announced this significant capital infusion, which is intended to bolster its efforts in the field of RNA interference (RNAi). The lead investor for this Series B round was not disclosed, nor were any other participating investors.
What City does
City operates within the biotech sector, with a specific focus on RNAi technology. The company’s stated ambition is to establish the foundational elements for a resurgence in RNAi applications. RNAi is a biological process in which RNA molecules inhibit gene expression or translation, by neutralizing targeted mRNA molecules. City’s work aims to harness this mechanism for therapeutic purposes.
What the funding will do
The capital raised in this Series B round is earmarked to “lay the foundation for an RNAi renaissance.” This indicates a strategic investment in research and development, aiming to advance the understanding and application of RNAi technology. While specific details on hiring, expansion, or go-to-market strategies were not provided, the overarching goal suggests a significant commitment to developing and expanding the potential of RNAi within the biotech landscape.
Why it matters
This funding round for City underscores continued investor interest in the RNAi therapeutic space. RNAi, once a highly promising but challenging area of drug development, has seen renewed attention due to advancements in delivery mechanisms and target specificity. A “renaissance” in RNAi, as City aims to foster, would signify a period of significant innovation and potentially new therapeutic breakthroughs for a range of diseases. The substantial investment in City reflects confidence in the company’s approach to overcoming previous hurdles and unlocking the full potential of RNAi technology. This could lead to the development of novel treatments and a deeper understanding of gene regulation, impacting various areas of medicine.